Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Giardia lamblia | Triosephosphate isomerase, cytosolic | 0.0091 | 0.7857 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0073 | 0.5371 | 0.6836 |
Loa Loa (eye worm) | hypothetical protein | 0.0073 | 0.5371 | 0.5371 |
Loa Loa (eye worm) | triosephosphate isomerase | 0.0091 | 0.7857 | 0.7857 |
Plasmodium falciparum | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Leishmania major | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Entamoeba histolytica | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Chlamydia trachomatis | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Mycobacterium tuberculosis | Probable triosephosphate isomerase Tpi (TIM) | 0.0091 | 0.7857 | 1 |
Echinococcus granulosus | proteasome prosome macropain | 0.007 | 0.4982 | 0.634 |
Mycobacterium leprae | Probable triosephosphate isomerase Tpi (TIM) | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0107 | 1 | 1 |
Echinococcus granulosus | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.007 | 0.4982 | 0.634 |
Brugia malayi | Proteasome A-type and B-type family protein | 0.007 | 0.4982 | 0.4982 |
Brugia malayi | triosephosphate isomerase | 0.0091 | 0.7857 | 0.7857 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0073 | 0.5371 | 0.5371 |
Trypanosoma cruzi | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Plasmodium vivax | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Toxoplasma gondii | triose-phosphate isomerase TPI-II | 0.0091 | 0.7857 | 1 |
Treponema pallidum | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Schistosoma mansoni | triosephosphate isomerase | 0.0037 | 0.0429 | 0.0546 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.007 | 0.4982 | 0.6129 |
Mycobacterium ulcerans | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.007 | 0.4982 | 0.4982 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.007 | 0.4982 | 0.634 |
Echinococcus multilocularis | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Toxoplasma gondii | triose-phosphate isomerase TPI-I | 0.0091 | 0.7857 | 1 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.007 | 0.4982 | 0.6129 |
Schistosoma mansoni | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Trypanosoma brucei | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0107 | 1 | 1 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 12 % | Growth inhibition of human MCF7 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 15 % | Growth inhibition of human A549 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 22 % | Growth inhibition of human PC3 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 42 % | Growth inhibition of human OVCAR5 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 51 % | Growth inhibition of human IMR32 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 53 % | Growth inhibition of human HeLa cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 62 % | Growth inhibition of human THP1 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.